| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $3,180,620 ) |
| 2024 | 2024 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R25TW012219 | Establishing an MSc in Global Health Ethics at the University of Cape Town | 000 | 3 | NIH | 3/23/2024 | $208,798 |
| 2024 | 2024 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | D71TW012504 | A Training Development Plan for HIV-associated Behavioural Medicine | 000 | 2 | NIH | 1/29/2024 | $25,000 |
| 2024 | 2024 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | D71TW012504 | A Training Development Plan for HIV-associated Behavioural Medicine | 000 | 2 | NIH | 1/29/2024 | $5,240 |
| 2024 | 2024 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R21HD110305 | Influence of fetal antiretroviral exposure on gut microbiota, systemic inflammation and neurodevelopment in infants exposed to HIV | 000 | 2 | NIH | 2/9/2024 | $140,547 |
| 2024 | 2024 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R21HD114232 | Functional longevity of maternally derived antibodies against group B Streptococcus and respiratory syncytial virus in HIV-exposed uninfected and HIV-unexposed uninfected infants. | 000 | 1 | NIH | 1/11/2024 | $150,257 |
| 2024 | 2024 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | U01MH125053 | 3/3 Genomics of Schizophrenia in the South African Xhosa | 000 | 4 | NIH | 3/1/2024 | $695,638 |
| 2024 | 2024 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI143636 | Host blood biomarkers for the diagnosis prognosis and treatment response of childhood TB | 000 | 5 | NIH | 2/14/2024 | $728,180 |
| 2024 | 2024 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | UM1AI069519 | HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | 000 | 18 | NIH | 11/2/2023 | $466,601 |
| 2024 | 2024 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | UM1AI069519 | HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | 000 | 18 | NIH | 11/2/2023 | $888,264 |
| 2024 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | U01TW012626 | INnovative data Science to Impact the TB Epidemic - INSITE | 000 | 1 | NIH | 3/6/2024 | $0 |
| 2024 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01MH131022 | Early brain development in children born to depressed mothers in high and low income settings | 000 | 2 | NIH | 3/6/2024 | $0 |
| 2024 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | K43TW011436 | Development of an HIV infection model of human foreskin to obtain novel insights into virus transmission | 001 | 4 | NIH | 1/8/2024 | $0 |
| 2024 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | K43TW011436 | Development of an HIV infection model of human foreskin to obtain novel insights into virus transmission | 000 | 4 | NIH | 1/8/2024 | -$97,599 |
| 2024 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | U01TW012626 | INnovative data Science to Impact the TB Epidemic - INSITE | 000 | 1 | NIH | 3/6/2024 | $0 |
| 2024 | 2022 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | K43TW011986 | Defining the biology of HIV-associated aggressive B-cell lymphoma in Southern Africa | 000 | 2 | NIH | 11/28/2023 | -$9,733 |
| 2024 | 2021 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152183 | Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study) | 001 | 2 | NIH | 3/21/2024 | -$192,462 |
| 2024 | 2021 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152183 | Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study) | 001 | 2 | NIH | 3/21/2024 | $192,462 |
| 2024 | 2021 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152118 | Biological effects, hormone levels and mechanisms relevant to HIV-1 infection for women randomized to the injectable contraceptives depo-medroxyprogesterone acetate or norethisterone enanthate. | 001 | 2 | NIH | 3/21/2024 | -$192,500 |
| 2024 | 2021 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152118 | Biological effects, hormone levels and mechanisms relevant to HIV-1 infection for women randomized to the injectable contraceptives depo-medroxyprogesterone acetate or norethisterone enanthate. | 001 | 2 | NIH | 3/21/2024 | $192,500 |
| 2024 | 2021 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152115 | Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa | 001 | 2 | NIH | 3/21/2024 | -$278,954 |
| 2024 | 2021 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152115 | Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa | 001 | 2 | NIH | 3/21/2024 | $278,954 |
| 2024 | 2021 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | U54HG009824 | Center for Research on the Respiratory Microbiota of African Children (ReMAC) | 000 | 5 | NIH | 2/8/2024 | $0 |
| 2024 | 2021 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | U01HG009716 | Hearing Impairment Genetics Studies in Africa (HI-GENES Africa) | 000 | 5 | NIH | 2/8/2024 | -$20,573 |
| 2024 | 2021 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | U01MH115484 | Transgenerational Effects of Maternal Stressors: Investigating the Role of Infant Gene Expression | 000 | 5 | NIH | 2/9/2024 | $0 |
| 2024 | 2021 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | U01MH115484 | Transgenerational Effects of Maternal Stressors: Investigating the Role of Infant Gene Expression | 000 | 5 | NIH | 2/9/2024 | $0 |
| 2024 | 2020 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152118 | Biological effects, hormone levels and mechanisms relevant to HIV-1 infection for women randomized to the injectable contraceptives depo-medroxyprogesterone acetate or norethisterone enanthate. | 000 | 1 | NIH | 3/14/2024 | -$192,500 |
| 2024 | 2020 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152118 | Biological effects, hormone levels and mechanisms relevant to HIV-1 infection for women randomized to the injectable contraceptives depo-medroxyprogesterone acetate or norethisterone enanthate. | 000 | 1 | NIH | 3/14/2024 | $192,500 |
| 2024 | 2020 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152183 | Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study) | 000 | 1 | NIH | 3/14/2024 | -$192,453 |
| 2024 | 2020 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152183 | Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study) | 000 | 1 | NIH | 3/14/2024 | $192,453 |
| 2024 | 2020 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152115 | Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa | 000 | 1 | NIH | 3/14/2024 | -$279,542 |
| 2024 | 2020 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152115 | Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa | 000 | 1 | NIH | 3/14/2024 | $279,542 |
| 2024 | 2020 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152092 | Repurposing kinase inhibitor chemotypes as antimalarials | 000 | 1 | NIH | 3/14/2024 | -$171,500 |
| 2024 | 2020 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152092 | Repurposing kinase inhibitor chemotypes as antimalarials | 000 | 1 | NIH | 3/14/2024 | $171,500 |
|
| Issue Date FY: 2023 ( Subtotal = $14,237,464 ) (Continued on the next page) |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R61DA053736 | Cape Town Adolescent Antiretroviral Cohort- Substance, Imaging, Mental Health (CTAAC-SIM) | 000 | 3 | NIH | 6/20/2023 | $358,953 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | K43TW011434 | Undetectable and Untransmittable: reducing HIV transmission among young women living with HIV, their partners and children in South Africa | 000 | 5 | NIH | 4/25/2023 | $50,000 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | K43TW011442 | Psychosocial distress, inflammatory reactivity and central sensitization in the pathway to HIV-related pain: characterizing the associations and developing a pragmatic, coping-focused intervention. | 000 | 5 | NIH | 4/10/2023 | $98,612 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01MH132950 | 3/3 Akili: Phenotypic and genetic characterization of ADHD in Kenya and South Africa | 001 | 1 | NIH | 9/4/2023 | $0 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01MH132950 | 3/3 Akili: Phenotypic and genetic characterization of ADHD in Kenya and South Africa | 000 | 1 | NIH | 7/26/2023 | $539,996 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | UM1AI069519 | HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | 001 | 17 | NIH | 5/30/2023 | $329,187 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | UM1AI069519 | HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | 001 | 17 | NIH | 5/30/2023 | $888,264 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | RONDEBOSCH | | | | ZAF | UM1AI069519 | HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | 000 | 17 | NIH | 11/25/2022 | $329,188 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | RONDEBOSCH | | | | ZAF | UM1AI069519 | HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | 000 | 17 | NIH | 11/25/2022 | $427,911 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | U01TW012626 | INnovative data Science to Impact the TB Epidemic - INSITE | 000 | 1 | NIH | 8/28/2023 | $1 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | U01TW012626 | INnovative data Science to Impact the TB Epidemic - INSITE | 000 | 1 | NIH | 8/28/2023 | $244,783 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | D71TW012568 | Developing an in vivo infectious disease training program at the University of Cape Town | 000 | 1 | NIH | 8/28/2023 | $109,774 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI143521 | New tools for antimalarial target identification | 000 | 5 | NIH | 2/24/2023 | $140,553 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152115 | Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa | 002 | 4 | NIH | 7/6/2023 | $0 |
| 2023 | 2023 | UNIVERSITY OF CAPE TOWN | LOVERS WALK | CAPE TOWN | | | | ZAF | R01AI152115 | Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa | 002 | 4 | NIH | 7/6/2023 | $0 |
|